GlobeNewswire

LeoVegas strengthens Group Management team and increases focus on LeoSafePlay and sustainability

Dela

LeoVegas Group is making several changes to its Group Management with the aim to optimise work on driving the Company's strategic agenda for sustainability and the ongoing journey of growth, with a further intensified focus on responsible gaming and LeoSafePlay.

New COO in Malta
Richard Woodbridge has been recruited as LeoVegas' new Chief Operating Officer (COO) and will have overarching responsibility for operations at LeoVegas' offices in Malta. Richard will assume his new role by 7 January 2019 at the latest and will be a member of LeoVegas' Group Management.

"LeoVegas is the leading GameTech company in the industry, and I have a passion for working with fast-growing tech companies," says Richard Woodbridge. "I am looking forward to being part of LeoVegas' continued journey of growth and optimising LeoVegas' operations, with sustainability as a guiding principle."

Richard Woodbridge joins LeoVegas from his role as COO of Ellos Group, and prior to this he held a corresponding position at the fast-growing e-commerce company Nelly.com.

Gustaf Hagman, Group CEO, comments: "Richard's background and personality are a perfect fit for LeoVegas as we continue to focus on growth and sustainability. Overarching responsibility for operations is growing increasingly important now that we have some 750 employees, of whom 400 are based in Malta. LeoVegas is a data-driven company in which we use a number of key metrics to further improve ourselves and increase our productivity. This has become even more crucial as we have begun acquiring companies and working with multiple brands. With his experience and capacity Richard will make a major contribution to our growth going forward."

LeoVegas' current COO, Marcus Nylén, will continue serving in that role in Malta through autumn 2018 until Richard takes office. Due to Marcus and Louise Nyléns relationship as closely related persons, Marcus will leave the Group Management when Richard joins to focus entirely on his role as head of LeoVegas' global expansion.

New Deputy CEO
Louise Nylén will assume the newly created role of Deputy CEO of LeoVegas Mobile Gaming Group, stationed in Stockholm. Louise was formerly Chief Marketing Officer (CMO) of LeoVegas. In her role as Deputy CEO she will work side by side Group CEO Gustaf Hagman with strategic issues such as sustainability and value-creating projects, among other things. Louise will assume her new position in the Company today the 10th of July.

"In my new role as Deputy CEO I will have a broader platform to work from, which will enable me to promote sustainability, growth and value for the Company," comments Louise Nylén. "I am very excited to have this trust and opportunity to continue contributing to LeoVegas' rapid development."

"Louise has been with LeoVegas and based in Malta since 2013, holding the position as CMO since 2015," continues Gustaf Hagman, Group CEO of LeoVegas Mobile Gaming Group. "In that role she has built up a data-driven and effective market team that is responsible for LeoVegas' customer acquisition and global brand-building. Much of the approach in this work can be used across a broader front in the Company. Louise has also played a key role in building our company culture and driving sustainability, and I look forward to work with Louise and all other employees to achieve our financial targets for 2020 of at least EUR 600m in revenue and at least EUR 100m in EBITDA.

Louise's former role as CMO will be broken up into several roles in Malta and will thereby be phased out.

LeoSafePlay - new business unit for next generation responsible gaming system
Rikard Ljungman is leaving his position as Chief Commercial Officer (CCO) as well as LeoVegas' Group Management to focus entirely on responsible gaming and LeoSafePlay. LeoSafePlay will be run as a separate business unit in order to create the best conditions for the next generation responsible gaming system based on machine learning.  Richard Woodbridge will take over Rikard Ljungman's CCO-related duties in Malta.

"Rikard was one of the initiative-takers behind LeoSafePlay, and with his strong product background, including as CPO for the software company Episerver, he has the exact right expertise to take the next step to make LeoVegas the leader in responsible gaming technology and strengthen our position as a GameTech company," comments Gustaf Hagman, Group CEO.

For further information, please contact :

Gustaf Hagman, Group CEO and co-founder: +46-(0)8-410 367 66, gustaf.hagman@leovegas.com
Philip Doftvik, Head of Investor Relations: +46-(0)73-512 07 20, philip.doftvik@leovegas.com

About the LeoVegas mobile gaming group
LeoVegas' passion is "Leading the way into the mobile future". LeoVegas is Sweden's premier GameTech company and is at the forefront of using state-of-the-art technology for mobile gaming. In 2017 the company passed the threshold for being classified as a unicorn, i.e., a start-up valued at more than USD 1 billion. A large part of this success can be credited to an extreme product and technology focus coupled with effective and data-driven marketing. Technology development is conducted in Sweden, while operations are based in Malta. LeoVegas offers casino, live casino and sports betting, and operates two global and scalable brands - LeoVegas and Royal Panda - as well as a local, multibrand operator collectively referred to as Rocket X. The company's shares are listed on Nasdaq Stockholm. For more about LeoVegas, visit www.leovegasgroup.com .




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LeoVegas AB via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum